CD274 and non-small cell lung carcinoma: For example, objective responses to PD-1 immunotherapies for NSCLC were reported to range from 19.0–21.0% and objective responses to PD-L1 immunotherapies for NSCLC were reported to range from 10.0–23.0% [1, 2].